insul dx focu
commentari perform reson tone
durabl devic pressur expect dx upsid
materi nutrit epd diabet drove
quarter remain insul remain overweight pt
quarter abbott deliv sale ahead
mse reflect organ growth total revenu came
estim devic impact in-lin peer
deliv normal see exhibit expect print
tuesday suggest see nutrit epd show strength quarter
deliv organ growth respect growth rate
pt mse segment strongest quarter nutrit
year covid-driven bulk drove increment sale
devic weaker exit quarter expect y/i
last week march diabet except driven ex-u libr sale
ahead mse robust new patient start total libr growth drove
nearli pt abbott organ growth quarter see exhibit ep
ahead mse driven top-line beat slightli lower
tax margin gross margin oper margin in-lin
model highlight summari result vs mse
medic technolog unit state america
unless otherwis note metric base modelwar
consensu data provid thomson reuter estim
seek busi
compani cover morgan stanley research
result investor awar firm may
conflict interest could affect object
morgan stanley research investor consid
morgan stanley research singl factor make
invest decis
analyst certif import disclosur
refer disclosur section locat end
exhibit diabet nutrit epd abbott pillar insul
mse assumpt chang sever manag
comment drive adjust model overal move bear
see origin base-to-bear analysi medic
devic except diabet rais number reflect
stronger momentum remaind year
cardio neuromod procedur like trend march-
end neuromod hardest-hit trend much
month april within cardio impact vari ep vascular
impact heart failur durabl rel basi
cardio neuro revenu move
reflect organ
growth reflect prior bear base case assumpt
assum diagnost segment exit march y/i shift
underli diagnost estim reflect
headwind roughli off-set dx upsid see
expect id-now serolog exhibit net
model dx revenu vs pre-covid
diabet singl greatest driver ou libr strength
result broadli confirm durabl diabet devic
group phase devic describ given
expect insul libr rais number
underli still declin y/i total drive
bp corpor read-through broadli
posit though consider includ patient access pharmaci
type mix stock assum saw slightli greater stock
march similar libr broadli durabl patient base
relat recoveri commentari consist mse
whose manag team spoke optimist recoup
continu model near-norm revenu model full recoup
slightli ahead prior consensu guidanc formal withdrawn
ceo robert ford express comfort current consensu
suggest compani may consid provid updat later
adjust segment-level impact model describ
updat fx impact align compani guidanc
impact sale model revenu use
margin drop oper margin revenu taken
model ultim reach ep pre-covid
diagnost test debat profil strateg financi
implic diagnost recent today call
chang view materi remain optimist test play
critic role re-open economi contain outbreak ultim
direct polici vaccin sens today call demand
larg meet abbott capac id-now antibodi test although
platform may ultim see usag slightli capac given
step time requir process test assumpt platform
shown exhibit abbott also expect launch later flow test
igm antibodi test near term sever key diagnost controversi remain
serolog perform accur poc later flow
consist architect infecti assay accuraci rate upper-
recent quot sen spec abbott
test lag sero-convers less clear
time frame level igg igm antibodi titer
necessari detect
rel insul clear remain overweight pt sinc mid-
februari vocal expect phase stock
out-performance includ defens diversifi name abbott
insul name case potenti driven benefit
baxter bd hillrom howev overweight abbott thesi
predic year compani premium top bottom-lin
growth profil rel basi intact current crisi
adjust price reflect ep premium
large-cap devic peer consist previou methodolog catalyst
libr remain delay although current-gen growth rate suggest
product evolut may matter less mitraclip ncd
origin expect april may
million except
exhibit abbott devic context result includ pre-announc thu far
dollar million except per share data
product sale
rev normal
base case methodolog base multipl base case ep
premium larg cap med-tech
abbott organ growth sustain
driven broad busi momentum
key product growth libr
abbott high exposur emerg
market consumer-direct busi
drive potenti sustain double-
digit earn growth also subject
compani em currenc exposur
highest among devic coverag
leverag opportun visibl across
nutrit diagnost epd peer
margin demonstr potenti
view descript risk reward theme
thomson reuter morgan stanley research morgan stanley institut equiti divis probabl
bull base bear case scenario play estim impli volatil data option market
apr gure approxim risk-neutr probabl stock reach beyond scenario price
either three-month one-year time view explan option probabl methodolog
durabl even clearer expect
newer product launch libr
quicker expect upsid synergi
robust em end market provid
rel insul
headwind clear abbott maintain
premium top bottom-lin prole
rel peer
diabet devic segment hit
harder expect
diagnost demand fail meet suppli
abbott invest grow revenu
offset margin improv em
organ growth acceler driven devic
product launch diabet ep
continu oper margin expans core
abbott combin cost synergi execut
st jude aler
china india
view explan region hierarchi
research highest favor quintil
upsid anticip
libr mitraclip alin grow faster
diagnost demand fail meet suppli
capac devic see harder hit
headwind strengthen us dollar
failur libr mitraclip alin drive
fund exposur held mspb inform may
inconsist may reect broader market
exposur sector total net exposur
across sector long exposur short exposur
